Antibody-conjugated mesenchymal stromal cell drug delivery system for the treatment of autoimmune diseases in mice

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Autoimmune diseases (AIDs), such as psoriasis and rheumatoid arthritis, are driven by immune dysfunction, leading to chronic inflammation and tissue damage. Mesenchymal stromal cells (MSCs) possess immunomodulatory and tissue repair properties; however, the therapeutic applicability of MSCs faces limitations due to the low homing efficiency upon systemic infusion. Inspired by antibody-drug conjugates (ADC), here we develop an antibody-conjugated MSC-based drug delivery system (AcM-DDS) that combines CD4 monoclonal antibody-conjugated MSC (CD4-mBMSC) with liposome-encapsulated Cedirogant, a RORγt inverse agonist. AcM-DDS targets CD4⁺ T cells, key drivers of AID, and precisely delivers RORγt antagonists to suppress Th17-mediated inflammation. In mouse models of imiquimod-induced psoriasis and collagen-induced arthritis, AcM-DDS enhances MSC homing to inflamed tissues, reduces Th17 activity, lowers pro-inflammatory cytokine production, and preserves cartilage and bone integrity. Thus, our results indicate the promising applicability of our engineered platform for targeted immune modulation and provide support for the suitability of this therapeutic approach for the treatment of AIDs.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.